T1000	Negation 500 503	not
E1000	Negation:T1000 Scope:T1001
T1001	Span 500 522	not a catalytic mutant
T1002	Negation 221 228	without
E1001	Negation:T1002 Scope:T1003
T1003	Span 221 271	without reversing Mdm2-mediated p53 ubiquitination
T1004	Speculation 1155 1160	could
E1002	Speculation:T1004 Scope:T1005
T1005	Span 1155 1241	could contribute to the decrease in MdmX expression following treatment with cisplatin
T1006	Speculation 1111 1119	suggests
E1003	Speculation:T1006 Scope:T1007
T1007	Span 1111 1241	suggests that the reduction in USP2a levels could contribute to the decrease in MdmX expression following treatment with cisplatin
T1008	Speculation 1399 1402	may
E1004	Speculation:T1008 Scope:T1009
T1009	Span 1399 1436	may be an approach for cancer therapy
T1010	Speculation 1319 1330	raising the
E1005	Speculation:T1010 Scope:T1011
T1011	Span 1319 1436	raising the possibility that suppression of USP2a in combination with cisplatin may be an approach for cancer therapy
